Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 9/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729432 | 0.82 | LMNA (0.40) | BRD4NOTUMLMNA | |
| SCHEMBL22729607 | 0.80 | BRD4 (0.47) | BRD4LMNA | |
| SCHEMBL22729514 | 0.77 | NOTUM (0.37) | BRD4NOTUMLMNAL3MBTL1 | |
| SCHEMBL22729829 | 0.73 | BRD4 (0.50) | BRD4NOTUM | |
| SCHEMBL22729486 | 0.72 | BRD4 (0.65) | BRD4L3MBTL1 | |
| SCHEMBL11610011 | 0.70 | BRD4 (0.56) | BRD4NOTUMLMNAP2RX7 | |
| SCHEMBL11560371 | 0.70 | NOTUM (0.55) | BRD4NOTUMLMNACHRM1P2RX7 | |
| SCHEMBL22729500 | 0.69 | KDM4E (0.49) | BRD4NOTUMLMNAL3MBTL1MAPK1 | |
| SCHEMBL22729637 | 0.69 | BRD4 (0.51) | BRD4L3MBTL1 | |
| SCHEMBL11577881 | 0.69 | LMNA (0.59) | NOTUMLMNACHRM1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | BRD4 1170/4885NOTUM 757/4885LMNA 695/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | BRD4 1201/4885NOTUM 715/4885LMNA 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.